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Abstract 
Objective: Carotenoids (including zeaxanthin and lycopene) and phytosterols reportedly confer 
beneficial effects on metabolic profile and function, which is of clinical importance. Thus, we 
sought to systematically review and meta-analyze the effects of saffron on waist circumstance 
(WC), fasting plasma glucose (FPG), and HA1C concentrations reported in Randomized Control 
Trials (RCTs).  
Method: A comprehensive systematic electronic search was performed in PubMed/MEDLINE, 
Embase, Google Scholar, Cochrane, Web of sciences, and SCOPUS to identify RCTs up to 
February 2019 without any language restrictions. The pooled weighted mean difference (WMD) 
calculated with DerSimonian-Laird random. PRISMA guidelines adhered to for this meta-analysis.  
Result: Nine articles with 12 arms containing 595 participants were included in the meta-analysis. 
Our study found WC was significantly reduced (WMD: -2.18 cm, 95% CI: -4.05, -0.32) and FPG 
(WMD: -6.54 mg/dl, 95% CI: -10.22, -2.85) following saffron intervention. Subgroup analysis 
highlighted that FPG levels (WMD: -10.24 mg/dl, 95% CI: -15.76, -4.72) reduced significantly 
when intervention duration was longer than twelve weeks. There was no significant effect on 
HA1C levels (WMD: -0.13 mg/dl, 95% CI: -0.31, 0.04) following saffron intervention.  
Conclusion: In conclusion, the present study indicates beneficial effects on WC and FPG, 
following saffron supplementation. 





Type 2 diabetes (T2D) is a prevalent, global disease, and associated with several comorbidities, 
such as hyperlipidemia, hypertension, and retinopathy, all of which increase the risk of mortality 
(Chen et al., 2012; Deshpande et al., 2008; Luk et al., 2017; Rashedi et al., 2017). In contemporary 
clinical practice, fasting blood glucose (FPG), hemoglobin A1c (HbA1c) and waist circumference 
are used to detect and monitor diabetes mellitus and metabolic syndrome, and treating or managing 
such factors represent important clinical goals. The prevalence of abnormal glucose regulation is 
nearly 40% in patients with coronary artery disease too (17). The normal range for FPG is 
considered to be 70 to 100 mg/dl, whilst levels between 100 and 126 mg/dl demarcate diminished 
fasting glucose levels and considered emblematic of pre-diabetes; whilst diabetes is traditionally 
diagnosed at FPG thresholds of 126 mg/dl or higher(Ghazanfari et al., 2010). HbA1c, or glycated 
hemoglobin, is hemoglobin with glucose attached and its’ measurement represents the average 
amount of glucose in the blood in the preceding 2-3 months. The reference range for HbA1c level 
in a healthy person is 4.8-5.7%, whilst ≥6.5% is representative of diabetes (Ghazanfari et al., 2010).  
Dietary management, physical activity and lifestyle modifications are shown to be variably 
efficacious in controlling diabetes and associated comorbidities, and therein represent major 
clinical research problems; particularly given the prevalence of T2D in both developed and 
developing countries (Deshpande et al., 2008; D. Skrypnik et al., 2019; Stepien et al., 2018). In 
recent times, herbal medicines have been used as complementary medicines to improve the 
regulation of glycemic metabolism in diabetic patients, with moderate success, and may represent 
a viable adjunct therapy to alleviate current clinical challenges (Paria Azimi et al., 2014; Cicero & 
Colletti, 2016; Deshpande et al., 2008; Jiang et al., 2011; Patti et al., 2018; K. Skrypnik et al., 
2019). Saffron (crocus sativus) is a perennial plant that consists of more than 300 volatile and non-
volatile compounds such as safronal, crocin, pirocrocin and some other carotenoids(Fi I Abdullaev, 
1993). Several investigations have shown positive pharmacological effect of crocin such as 
anticancer, antidepressant, anti-ischemic, hypotensive, inflammatory and antioxidant activities 
(Fikart I Abdullaev, 2002; Aung et al., 2007; Hossein Hosseinzadeh et al., 2009; H Hosseinzadeh 
& Ziaei, 2006; Imenshahidi et al., 2010). In a study by Shirali et al, saffron, as a traditional 
medicine and food additive, has the potential to elicit anti-diabetic effects(Shirali et al., 2012). 
Furthermore, previous studies have demonstrated that crocin (a carotenoid in saffron) improves 
insulin secretion and reduces insulin resistance(Bathaie & Mousavi, 2010). In an animal model, 
Xi and colleagues reported that crocin supplementation can elicit positive changes in insulin 
resistance, hyperinsulinemia, dyslipidemia and hypertension (Tayebe Kermani et al., 2017). 
However, these effects are yet to be demonstrated in humans. 
Although supplementation with saffron, or its derivatives, has been shown to positively effect 
clinically relevant biomarkers; thus far, there has been no meta-analytical evaluation of the 
beneficial effects of saffron on FPG, HbA1c and waist circumference. Therefore, the aim of the 
present study was to evaluate the efficacy of saffron on FPG, HbA1c and WC in randomized 
clinical trials. 
2. Methods 
2.1. Study design and Search strategy 
This meta-analysis was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2015). 
A systematic search was performed in PubMed/MEDLINE, Embase, google scholar, Cochrane, 
Web of sciences, and SCOPUS to locate relevant studies. Randomised controlled trials (RCTs) 
investigating the effect of Saffron on waist circumference and glucose metabolism compared with 
control group that received placebo. We systematically combined the search terms of the treatment 
(i.e. saffron therapy) and the outcome variables (i.e. waist circumference and Glucose 
metabolism). The search strategy was developed with no language restriction, from database 
inception until February 2019. The search strategy is detailed in the supplementary Table 1.   
2.2. Selection criteria 
The PICOTS criteria were used to select included articles following P: non-communicable 
patients, I: intervention by saffron, C: intervention by placebo, O: waist circumference and glucose 
metabolism, T: inception until February 2019, Study design: Randomized controlled trials. 
Endnote Reference Manager X8© was used to store identified studies. The inclusion criteria 
consisted of the following: 1) Adult subjects (18 years and older); 2). RCT design; 3) mean 
differences with standard deviations before and after of intervention for outcomes are reported; 4). 
Studies that examined the effects of Saffron or Crocin; 5) Studies that reported waist circumference 
or/and fasting blood sugar or/and HbA1c as measured outcome. The exclusion criteria were:  1) 
Treatments other than Saffron; 2) Animal studies; 3) Studies with non RCT design; 4) Studies 
without a placebo group; 5) Conference abstracts, case-reports, reviews, and commentaries; 6) 
studies on mental disease. Two authors (JR and EB) independently screened the titles, abstracts 
and full-texts, respectively, at each stage of the reviewing process.  
2.3. Data extraction 
Two researchers (JR and EB) independently extracted relevant data from studies using a 
standardised form. Any disagreements were resolved by cooperative triangulation with a senior 
author (SSHN). The following details were recorded in the standardised form: study authors, 
location, year of publication, duration of follow up, sample size in intervention and control groups, 
mean age of participants, Saffron dose, Saffron type, participants disease type, and mean and 
standard deviation (SD) of outcome pre- and post-intervention. We contacted the authors of 
included papers for any additional information required. 
2.4. Risk of bias assessment 
The “Cochrane collaboration’s tool for quality assessment of randomized control trials” was 
employed to examine risk of bias assessment of included studies (Higgins et al., 2011), consisting 
of the following items: Selection bias (random sequence generation and allocation concealment), 
completeness of outcome data, other sources of bias, performance bias, outcome bias, and attrition 
bias. 
2.5. Statistical analysis 
Studies providing estimates of weighted mean differences (WMD) and standard deviations were 
combined. The DerSimonian and Laird random-effects model was used to calculate the pooled 
WMD. When the standard error (SE) of the mean difference was reported for studies SD was 
calculated by the following formula: SD2 baseline + SD2 final – (2 R* SD baseline + SD final) (Cooper et 
al., 2009). The Q-test, the I-squared statistic, and an alpha level of 0.05 were used to assess the 
heterogeneity between studies based on the Cochrane thresholds recommendations (Green & 
Higgins, 2005). Subgroup analyses based on duration of intervention (12 weeks < or +12 weeks) 
was used to identify sources of heterogeneity among the included studies. Saffron type (Saffron, 
Crocin, or Saffron extract) was predefined as a source of heterogeneity. The funnel plot and the 
Egger’s tests were used to assess the probability of publication bias. All statistical analyses were 
performed using STATA 14 (StataCorp LP, College Station, USA), using an a priori p value of 
0.05 to represent statistical significance. 
3. Results 
In our primary systematic search 339 studies were identified from PubMed/MEDLINE, Scopus, 
Embase, Web of sciences, Cochrane Library and google scholar (Supplementary Figure 1). After 
removing duplicates, 232 studies were screened. After, screening based on titles and/or abstracts, 
187 studies were excluded, and 36 other studies were excluded in full text screening because of 
the following reasons: 1) Non-RCT design (n=5), 2) non-human trials, review or mental disease 
population (n=27), and 3) Not measure Waist Circumference, FPG or HbA1c as outcome (n=3). 
According to inclusion criteria, nine articles with 12 arms containing 595 participants were 
included in the meta-analysis(N. Abedimanesh et al., 2017; P. Azimi et al., 2014; Fadai et al., 
2014; A. Javandoost et al., 2017; T. Kermani, M. Zebarjadi, et al., 2017; A. Milajerdi et al., 2018; 
Nikbakht-Jam et al., 2016; Sepahi et al., 2018).  
3.1. Study characteristics 
Table 1 provides characteristics of eligible studies. Articles were published between 2014 to 2018. 
All studies were conducted in the Iran (N. Abedimanesh et al., 2017; P. Azimi et al., 2014; Fadai 
et al., 2014; A. Javandoost et al., 2017; T. Kermani, M. Zebarjadi, et al., 2017; A. Milajerdi et al., 
2018; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). There were 301 (range from 20-42 
individuals) participants in intervention group and 294 (range from 20-39 individuals) participants 
in control groups. The mean age of participant was 50.11 (6.24) years (50 (6.67) years in 
intervention groups and 50.58 (6.30) years in control groups). The mean duration of the study 
interventions was 9.5(from 6 to 12) weeks. The mean dose of the Saffron administered was 120 
mg/day (5 to 1000 mg/day). Three studies were conducted on patients with diabeties (P. Azimi et 
al., 2014; A. Milajerdi et al., 2018; Sepahi et al., 2018), five on patients with metabolic syndrome 
(Fadai et al., 2014; A. Javandoost et al., 2017; T. Kermani, M. Zebarjadi, et al., 2017; Nikbakht-
Jam et al., 2016), and one on coronary artery disease(N. Abedimanesh et al., 2017). Seven arms 
used Crocin (N. Abedimanesh et al., 2017; Fadai et al., 2014; A. Javandoost et al., 2017; T. 
Kermani, M. Zebarjadi, et al., 2017; Nikbakht-Jam et al., 2016; Sepahi et al., 2018) and five arms 
used Saffron (N. Abedimanesh et al., 2017; P. Azimi et al., 2014; Fadai et al., 2014; T. Kermani, 
M. Zebarjadi, et al., 2017; A. Milajerdi et al., 2018) as effective material in in   tervention. All 
studies were randomized controlled clinical trials (N. Abedimanesh et al., 2017; P. Azimi et al., 
2014; Fadai et al., 2014; A. Javandoost et al., 2017; T. Kermani, M. Zebarjadi, et al., 2017; A. 
Milajerdi et al., 2018; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). 
3.2. Quality assessment  
Fig 1 shows the results of the quality assessment of included studies. Most studies had low risk of 
bias(N. Abedimanesh et al., 2017; Fadai et al., 2014; A. Javandoost et al., 2017; T. Kermani, M. 
Zebarjadi, et al., 2017; A. Milajerdi et al., 2018; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). 
Only one study was rated as having a high risk of bias for performance bias and detection bias(P. 
Azimi et al., 2014). 
3.3. Meta-analysis results 
Waist Circumference (WC) 
Five studies with seven arms containing a total of 178 participants in intervention groups and 177 
participants in control groups reported waist circumference as an outcome measure(N. 
Abedimanesh et al., 2017; P. Azimi et al., 2014; Fadai et al., 2014; T. Kermani, T. Kazemi, et al., 
2017; T. Kermani, M. Zebarjadi, et al., 2017). Results were combined using random-effects model 
and showed significant reduction in waist circumference following Saffron intervention (WMD: -
2.18 cm, 95% CI: -4.05, -0.32) (Fig 2). There was no significant heterogeneity among studies 
(p=0.07, I2=47%). 
Fasting blood sugar (FPG) 
Nine studies (12 arms) providing 595 participants (intervention arm = 301, and control arm = 294) 
reported FPG as an outcome measure (N. Abedimanesh et al., 2017; P. Azimi et al., 2014; Fadai 
et al., 2014; A. Javandoost et al., 2017; T. Kermani, T. Kazemi, et al., 2017; T. Kermani, M. 
Zebarjadi, et al., 2017; A. Milajerdi et al., 2018; Nikbakht-Jam et al., 2016; Sepahi et al., 2018). A 
significant reduction was observed in the intervention group compared with the control group in 
pooled results from the random-effects model in FPG levels (WMD: -6.54 mg/dl, 95% CI: -10.22, 
-2.85) (Fig 3). There was a significant heterogeneity among studies (p=0.001, I2=68%). 
HBA1C 
Four studies with 6 arms provided 154 participants in the intervention groups and 147 participants 
in the control groups reported HbA1c as an outcome measure (P. Azimi et al., 2014; Fadai et al., 
2014; A. Milajerdi et al., 2018; Sepahi et al., 2018). Results were pooled by the random-effects 
model and indicated that Saffron or Crocin as interventions resulted in non-significant decrease in 
HbA1c levels (WMD: -0.13 mg/dl, 95% CI: -0.31, 0.04) (Fig 4). There was significant 
heterogeneity among studies (p=0.02, I2=61%). 
Subgroup analysis 
Table 2 demonstrated the results of the subgroup analyses. We performed sub-group analysis for 
FPG and HbA1c based on duration of intervention (12 weeks < or +12 weeks). Subgroup analysis 
showed that FPG levels (WMD: -10.24 mg/dl, 95% CI: -15.76, -4.72) reduced significantly when 
duration of intervention was more than 12 weeks compared with trials that had less duration 
(WMD: -3.77 mg/dl, 95% CI: -7.09, -0.46) but the duration of intervention did not show any 
significant difference in results of HbA1c. 
Publication bias 
Publication bias analysis was done by Egger’s and Begg tests. The Egger’s and Begg tests did not 
show publication bias for FPG (p=0.39 and p=0.41, respectively) and HbA1c (p=0.14, p=0.85) 
(Supplemental Fig 2). Furthermore, Begg tests did not show any publication bias for WC (p=0.29) 
but significant publication bias was identified for WC by Egger’s test (p=0.04) so we used ‘trim 
and fill’ method for adjusting publication bias (Supplemental Table 2).  
4. Discussion 
Non-pharmacological management or treatment of various non-communicable diseases typically 
involves a dietary and/or physical activity component; although recently, the use of adjunct 
therapies has proliferated. Phytochemicals, constituent within the diet, are considered combative 
against various non-communicable diseases (Baboota et al., 2013; Hasani-Ranjbar et al., 2009), 
particularly through regulation of lipid absorption, modulation of energy intake and expenditure, 
respectively, decreases in lipogenesis and increases in lipolysis, and differentiating pre-adipocyte 
proliferation (González-Castejón & Rodriguez-Casado, 2011). Saffron, and its’ constituents, 
reportedly contain innumerable beneficial properties, including anti-obesogenic, and conferring 
positive effects on clinically relevant biomarkers (Mashmoul et al., 2013). Thus, we sought to 
conduct a systematic review and meta-analysis to evaluate the efficacy of saffron on FPG, HbA1c 
and WC in randomized clinical trials. In accord with the aforementioned aim, we found that 
supplementation with saffron resulted in a significant reduction in waist circumference and fasting 
blood glucose, in addition to a non-significant decrease in HbA1c levels. Moreover, subgroup 
analysis showed that FPG levels reduced significantly when the intervention length was ≥12 
weeks, whilst the duration of intervention did not elicit significant differences in the results of 
HbA1c. Indeed, such results may be of clinical utility, given that saffron supplementation is easily 
implementable and tolerable to participants, whilst also not likely to elicit any undesirable side-
effects, or interactions with existing treatment regimens.  
Concomitant to the meta-analytical synthesis provided in this study, there is some prior clinical 
evidence to support the healthful effects of saffron on metabolic comorbidities. For instance; 
Ebrahimi et al reported that, compared with placebo, saffron supplementation yielded significant 
decreases in both WC, and malondialdehyde, a marker of oxidative stress(Ebrahimi et al., 2019). 
In addition to the positive metabolic effects, there have been reports of concurrent improvements 
in psychological facets related to treatment. Ghaderi et al investigated the effects of supplementing 
with a saffron derivative, crocin, on mental health, metabolic, and genetic profiles in patients 
undertaking a methadone maintenance treatment program for drug abuse disorders(Ghaderi et al., 
2019). Accordingly, Ghaderi et al reported that crocin yielded significant improvements in FPG, 
in addition to mental health and various other metabolic parameters; a finding that was avowed in 
Khalatbari-Mohseni et al. The aforementioned findings highlight that, in addition to the significant 
findings of our study, saffron confer broad, clinically important benefits(Khalatbari-mohseni et al., 
2019).  
Purported mechanistic action 
Saffron is thought to enhance lipid profile and glucose uptake via an insulin dependent pathway, 
resulting in the phosphorylation of AMP-activated protein kinases (AMPK), acetyl-CoA 
carbohydrate (ACC), and mitogen activated protein kinases (MAPKS); moreover, a combination 
of saffron and insulin has been reported to positively impact sensitivity to insulin (Kang et al., 
2012), albeit in animal-based studies. In human-based work, saffron, or its constituents, is show to 
confer beneficial changes to blood lipids and obesity indices. In Gout et al (Gout et al., 2010), it 
was suggested that significant reductions in body weight may be achieved as a result of saffron 
supplementation, whilst, Kermani et al (Tayyebe Kermani et al., 2017) demonstrated HDL and 
pro-oxidant balance improvements, and Abedimanesh et al in 2017 (Nasim Abedimanesh et al., 
2017) found that  BMI, waist circumference and fat mass values were all significantly improved. 
However, in comparison to animal-based work, the literature is more variable with respect to its 
effect on humans. Whilst a component of saffron, crocin, may =putatively possess beneficial 
effects on hyperlipidemia, hypertension and other blood lipid disorders (Alavizadeh & 
Hosseinzadeh, 2014), there exists equivocality in the literature. Some animal models have shown 
the efficaciousness of saffron/crocin in lowering blood glucose and enhancing the blood lipid 
profile, whilst, among others, Javandoost et al (Ali Javandoost et al., 2017) found no significant 
changes were evident in LDL, HDL or TG following saffron supplementation; similarly, Milajerdi 
et al (Alireza Milajerdi et al., 2018) reported no significant change in other metabolic parameters, 
including, serum lipids, blood pressure, and HbA1c. This inconsistency may conceivably be 
attributed to; varying samples (human vs. animal), varying relative doses, varying duration of 
supplementation and various methods of administration (Alavizadeh & Hosseinzadeh, 2014). 
Previous empirical work investigating the effects of carotenoids, such as crocin, on cardiovascular 
disease risk is noteworthy. Although some empirical data demonstrates the presence of a 
relationship between high dietary carotenoids intake and lower cardiovascular disease incidence, 
other work has shown that large doses of carotenoids are inconsequential, and in some cases, may 
be harmful (P. Giordano, 2012). However, most negative findings associated with carotenoids 
were observed with beta-carotene. Thus, concerns that have been asserted for beta-carotene 
supplementation may not apply to saffron/crocin. In fact, we found no reported injurious side-
effects due to saffron supplementation in the included studies, which is of great importance for 
clinical management of patients. 
Strength and limitations 
The principal strength of the present study was that this was the first to assess the impact of saffron 
supplementation on waist circumference and glucose metabolism in patients with non-
communicable diseases, following a meta-analytical framework; and given the potentially 
clinically relevant outcomes, this is an important finding. An additional strength of the present 
meta-analysis is the heterogeneous sample of participants present within the study. This is the first 
study to assess the impact of saffron supplementation on waist circumference and glucose 
metabolism in patients with non-communicable diseases, therein facilitating and providing 
guidance for further work. In addition to the aforementioned strengths, there are some limitations 
to the present study. For instance; the incumbent analyses did not include participants of one-
specific typology; whilst this enabled nine studies for inclusion in the analyses, there might be 
disease specific factors that require exploration. Some sample sizes were relatively small, which, 
compared to larger samples, can lead to spurious resultant effect sizes(Sterne & Egger, 2001); 
however, this was not within our control, and a robust meta-analytical procedure was followed to 
alleviate such concerns. A final limitation of our study was that there were only limited suitable 
studies available, and whilst we were able to ascertain overall positive and significant effects, there 
is a clear need for more high-quality RCT’s. 
5. Conclusion 
The results of the present study support the supplementation of saffron for the improvement of 
waist circumference and glucose metabolism, with sub-group analysis highlighting that FPG 
levels reduced significantly when intervention durations were ≥12 weeks. Given the positive 
results; saffron supplementation likely represents a clinically useful prospect, that is easily 
implementable and tolerable to participants, whilst also not likely to elicit any undesirable side-
effects, or interactions with existing treatment regimens. 
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